{ "schemaVersion": 1, "organisationId": "O-5273d8b9c9ad40e09dd07bf7c4446e75", "slug": "sartorius-stedim-biotech", "name": "SARTORIUS STEDIM BIOTECH", "updatedAt": "2026-10-04T14:38:23.069718Z", "sections": [ { "type": "OVERVIEW", "text": "Sartorius Stedim Biotech is a life-sciences supplier focused on technologies and services for biopharmaceutical development and manufacturing. Its portfolio includes solutions for cell-line development and media, bioreactors, separation and purification, and the storage and transport of biopharmaceutical products, with single-use technologies among its core offerings. [https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa] [https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf] The company’s stated mission is to help biopharma customers accelerate drug development and improve manufacturing efficiency, supporting the development of better therapies and more affordable medicine. [https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission]\n\nSartorius Stedim Biotech operates internationally, with a presence in around 30 countries and more than 50 locations. [https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf] For the year ended December 31, 2025, it reported revenue of €2,967.5 million and 10,265 employees. [T3222458] [T7123874]\n[https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa][https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf][https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission][https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf][T3222458][T7123874][https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa][https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf][https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission][https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf]", "updatedAt": "2026-10-04T14:38:23.069718Z" }, { "type": "PRODUCTS", "text": "Sartorius Stedim Biotech’s product portfolio supports biologics manufacturing across cell lines, cell-culture media and reagents; bioreactors; separation, purification and concentration; storage and transport; and process-modelling and optimization software. Applications include monoclonal antibodies, vaccines, antibody-drug conjugates, and cell and gene therapies. The company offers integrated process solutions, including scalable single-use technologies and solutions for intensified or continuous production. [P16983097][P42988454]\n\nExamples include the **Biostat STR Generation 3** single-use bioreactor, with working volumes from 12.5 to 2,000 L; **Sartopore Evo** sterilizing-grade PES membrane filters, including a 0.8 μm prefilter/0.2 μm final-filter configuration; **Flexsafe** single-use bags for fluid storage, shipping, filtration and transfer; and **Sartoflow Advanced**, a modular benchtop tangential-flow filtration system for ultrafiltration and diafiltration. [https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors/biostat-str][https://shop.sartorius.com/ww/p/sartopore-evo/M_Sartopore_Evo][https://www.sartorius.com/en/products/fluid-management/liquid-storage-shipping/flexsafe-liquid-storage-shipping][https://www.sartorius.com/en/products/process-filtration/tangential-flow-filtration/tff-systems/sartoflow-advanced]\n\nServices include process design, plant planning, validation support, bioprocess consulting and engineering, scale-up, process optimization and validation studies for single-use systems and conventional equipment. Sterile single-use products account for “a good three quarters” of sales revenue, with the share varying by product group and region; the cited report does not give a more granular revenue breakdown by individual product or service. [P42988454][https://www.sartorius.com/en/services/bioprocess-development-engineering][https://www.sartorius.com/en/services/validation-service][P107258085]\n[P16983097][P42988454][P107258085][https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors/biostat-str][https://shop.sartorius.com/ww/p/sartopore-evo/M_Sartopore_Evo][https://www.sartorius.com/en/products/fluid-management/liquid-storage-shipping/flexsafe-liquid-storage-shipping][https://www.sartorius.com/en/products/process-filtration/tangential-flow-filtration/tff-systems/sartoflow-advanced][https://www.sartorius.com/en/services/bioprocess-development-engineering][https://www.sartorius.com/en/services/validation-service]", "updatedAt": "2026-10-04T14:38:23.069718Z" }, { "type": "GEOGRAPHY", "text": "In 2025, Sartorius Stedim Biotech generated about 42% of sales in EMEA (€1,241.5 million), 35% in the Americas (€1,053.4 million) and 23% in Asia|Pacific (€672.6 million). North America and Asia are identified as focal areas in its regional growth strategy. [P12347253][P113431209] Country-level sales included €995.7 million in the United States, €255.8 million in Germany, €173.3 million in China, €157.2 million in South Korea and €120.9 million in France. [T1343065]\n\nAt year-end 2025, the company reported 7,131 employees in EMEA, 1,724 in the Americas and 1,410 in APAC. [T7123874] The parent company is based in Aubagne, France; its listed group entities span several countries, including France, Germany, Belgium, the United Kingdom and Israel. The company identifies a cell-culture-media facility in Beit HaEmek, Israel, and has also reported manufacturing and R&D expansions in Aubagne and Illkirch, France. [T2586962][P28107370][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747898][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364]\n[P12347253][P113431209][T1343065][T7123874][T2586962][P28107370][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747898][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364]", "updatedAt": "2026-10-04T14:38:23.069718Z" }, { "type": "SEGMENTS", "text": "Sartorius Stedim Biotech reports one operating business segment, **Biopharm**, which accounts for 100% of group sales. Its portfolio serves pharmaceutical and biotechnology companies and contract manufacturers, covering cell lines, culture media and reagents, bioreactors, separation and purification technologies, storage and transport solutions, and process-analysis software. In 2025, Biopharm sales were €2,967.5 million. [P56976948][T2016863][P16983097]\n\nGeography is disclosed as a sales view rather than a separate operating segment. In 2025, sales were approximately 42% EMEA, 35% Americas, and 23% Asia Pacific. The 2026 first-half report also presents regional sales, but does not identify additional business segments. [P12347253][https://www.sartorius.com/download/1845890/h1-2026-download-half-year-report-ssb-en-data.pdf]\n[P56976948][T2016863][P16983097][P12347253][https://www.sartorius.com/download/1845890/h1-2026-download-half-year-report-ssb-en-data.pdf]", "updatedAt": "2026-10-04T14:38:23.069718Z" }, { "type": "HISTORY", "text": "Stedim was founded in Aubagne, France, in 1978 by Bernard Lemaître and Bernard Vallot. In the early 1990s it developed single-use bag systems for biopharmaceutical manufacturing, and in 1994 it became publicly listed on the Paris stock exchange. [https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/history]\n\nOn June 29, 2007, Stedim merged with Sartorius’s Biotechnology Division to form Sartorius Stedim Biotech, which was listed on Euronext Paris. [https://www.sartorius.com/en/company/about-sartorius-ag/history/2007-today] The company subsequently expanded its bioprocess and development capabilities through acquisitions including TAP Biosystems in 2013, BioOutsource and Cellca in 2015, and Umetrics in 2017. [https://ir-reports.sartorius.com/fileadmin/images/ir_reference_document_2013_sartorius_stedim_biotech.pdf] [https://www.sartorius.com/download/32724/sag-q1-report-2015-e-data.pdf] [https://www.sartorius.com/download/38812/ssb-h1-report-2015-e-data.pdf] [https://www.sartorius.com/en/company/newsroom/corporate-news/17476-17476]\n\nFrom 2021 to 2023, acquisitions of CellGenix, Xell, Albumedix and Polyplus broadened its offerings for cell and gene therapies and other advanced biologics. [https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-strengthens-product-portfolio-for-cell-and-gene-therapies-by-acquiring-a-majority-stake-in-cellgenix-817522] [https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-acquires-cell-culture-specialist-xell-ag-922684] [https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-albumedix-1300590] [https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-polyplus-1452176] In 2025, the company completed an expansion at its Aubagne site, adding manufacturing, research and development, and logistics capacity. [https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364]\n[https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/history][https://www.sartorius.com/en/company/about-sartorius-ag/history/2007-today][https://ir-reports.sartorius.com/fileadmin/images/ir_reference_document_2013_sartorius_stedim_biotech.pdf][https://www.sartorius.com/download/32724/sag-q1-report-2015-e-data.pdf][https://www.sartorius.com/download/38812/ssb-h1-report-2015-e-data.pdf][https://www.sartorius.com/en/company/newsroom/corporate-news/17476-17476][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-strengthens-product-portfolio-for-cell-and-gene-therapies-by-acquiring-a-majority-stake-in-cellgenix-817522][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-acquires-cell-culture-specialist-xell-ag-922684][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-albumedix-1300590][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-polyplus-1452176][https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364]", "updatedAt": "2026-10-04T14:38:23.069718Z" } ], "sources": [ { "id": "https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa", "href": "https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf", "href": "https://www.sartorius.com/download/1725892/h1-2025-download-ir-fact-sheet-ssb-en-data.pdf", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission", "href": "https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/mission", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf", "href": "https://www.sartorius.com/download/1796564/fy-2025-download-urd-ssb-en-data.pdf", "label": "www.sartorius.com" }, { "id": "T3222458", "href": "https://app.finbar.com/go?id=T3222458", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p2", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 2 }, { "id": "T7123874", "href": "https://app.finbar.com/go?id=T7123874", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p176", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 176 }, { "id": "P16983097", "href": "https://app.finbar.com/go?id=P16983097", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p28", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 28 }, { "id": "P42988454", "href": "https://app.finbar.com/go?id=P42988454", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p28", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 28 }, { "id": "https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors/biostat-str", "href": "https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors/biostat-str", "label": "www.sartorius.com" }, { "id": "https://shop.sartorius.com/ww/p/sartopore-evo/M_Sartopore_Evo", "href": "https://shop.sartorius.com/ww/p/sartopore-evo/M_Sartopore_Evo", "label": "shop.sartorius.com" }, { "id": "https://www.sartorius.com/en/products/fluid-management/liquid-storage-shipping/flexsafe-liquid-storage-shipping", "href": "https://www.sartorius.com/en/products/fluid-management/liquid-storage-shipping/flexsafe-liquid-storage-shipping", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/products/process-filtration/tangential-flow-filtration/tff-systems/sartoflow-advanced", "href": "https://www.sartorius.com/en/products/process-filtration/tangential-flow-filtration/tff-systems/sartoflow-advanced", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/services/bioprocess-development-engineering", "href": "https://www.sartorius.com/en/services/bioprocess-development-engineering", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/services/validation-service", "href": "https://www.sartorius.com/en/services/validation-service", "label": "www.sartorius.com" }, { "id": "P107258085", "href": "https://app.finbar.com/go?id=P107258085", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p28", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 28 }, { "id": "P12347253", "href": "https://app.finbar.com/go?id=P12347253", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p36", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 36 }, { "id": "P113431209", "href": "https://app.finbar.com/go?id=P113431209", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p32", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 32 }, { "id": "T1343065", "href": "https://app.finbar.com/go?id=T1343065", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p279", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 279 }, { "id": "T2586962", "href": "https://app.finbar.com/go?id=T2586962", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p282", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 282 }, { "id": "P28107370", "href": "https://app.finbar.com/go?id=P28107370", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p54", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 54 }, { "id": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747898", "href": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747898", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364", "href": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698364", "label": "www.sartorius.com" }, { "id": "P56976948", "href": "https://app.finbar.com/go?id=P56976948", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p277", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 277 }, { "id": "T2016863", "href": "https://app.finbar.com/go?id=T2016863", "label": "SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y), p278", "documentId": "D-65a455d1711e44459261c9be5705dc24", "page": 278 }, { "id": "https://www.sartorius.com/download/1845890/h1-2026-download-half-year-report-ssb-en-data.pdf", "href": "https://www.sartorius.com/download/1845890/h1-2026-download-half-year-report-ssb-en-data.pdf", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/history", "href": "https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa/history", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/about-sartorius-ag/history/2007-today", "href": "https://www.sartorius.com/en/company/about-sartorius-ag/history/2007-today", "label": "www.sartorius.com" }, { "id": "https://ir-reports.sartorius.com/fileadmin/images/ir_reference_document_2013_sartorius_stedim_biotech.pdf", "href": "https://ir-reports.sartorius.com/fileadmin/images/ir_reference_document_2013_sartorius_stedim_biotech.pdf", "label": "ir-reports.sartorius.com" }, { "id": "https://www.sartorius.com/download/32724/sag-q1-report-2015-e-data.pdf", "href": "https://www.sartorius.com/download/32724/sag-q1-report-2015-e-data.pdf", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/download/38812/ssb-h1-report-2015-e-data.pdf", "href": "https://www.sartorius.com/download/38812/ssb-h1-report-2015-e-data.pdf", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/newsroom/corporate-news/17476-17476", "href": "https://www.sartorius.com/en/company/newsroom/corporate-news/17476-17476", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-strengthens-product-portfolio-for-cell-and-gene-therapies-by-acquiring-a-majority-stake-in-cellgenix-817522", "href": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-strengthens-product-portfolio-for-cell-and-gene-therapies-by-acquiring-a-majority-stake-in-cellgenix-817522", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-acquires-cell-culture-specialist-xell-ag-922684", "href": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-acquires-cell-culture-specialist-xell-ag-922684", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-albumedix-1300590", "href": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-albumedix-1300590", "label": "www.sartorius.com" }, { "id": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-polyplus-1452176", "href": "https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-completes-acquisition-of-polyplus-1452176", "label": "www.sartorius.com" } ] }